Drugs /

danvatirsen

Back to Drugs List

Overview

NCI Definition [1]:
An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. STAT3 antisense oligonucleotide ISIS 481464 binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.

Clinical Trials

View Clinical Trials for danvatirsen

Danvatirsen has been investigated in 7 clinical trials, of which 5 are open and 2 are closed. Of the trials investigating danvatirsen, 3 are phase 1 (2 open) and 4 are phase 2 (3 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for danvatirsen clinical trials.

Non-small cell lung carcinoma, malignant solid tumor, and aggressive non-hodgkin lymphoma are the most common diseases being investigated in danvatirsen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Danvatirsen
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Danvatirsen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating danvatirsen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
azd9150, isis 481464, stat3 antisense oligonucleotide isis 481464, isis-stat3rx
Drug Target(s) [2]:
STAT3
NCIT ID [1]:
C101368

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.